Claim 1-18 (canceled)

Claim 19 (currently amended): A method of providing an adjuvant effect to a vaccine comprising at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence comprising combining said antigen or in vivo generator with a surfactant or with a mixture of surfactants~~, said surfactant or mixture of surfactants~~ having an overall HLB number of between 5 and 15 and comprising:

- ethoxylated derivatives of ester of fatty acids having 12 to 22 carbon atoms with sorbitan or mannitan having a number of OE of between 1 and 60; or

-ethoxylated derivatives of oils having a number of OE of between 1 and 60.

Claim 20 (original): A method of providing an adjuvant effect to a vaccine as defined in Claim 19, wherein said vaccine does not include an oily phase.

Claims 21-29 (canceled)

B1

Claim 30 (original): The method as defined in Claim 19, wherein said vaccine is suitable for a mucosal vaccination.

Claim 31 (original): The method as defined in Claim 30, wherein said vaccine is suitable for application orally, nasally, rectally or vaginally.

Claim 32 (previously added): A process for enhancing the immune response to a vaccine comprising at least one antigen or at least one in vivo generator of a compound comprising an amino acid sequence, said process comprising combining said antigen or in vivo generator with a surfactant or with a mixture of surfactants, said surfactant or mixture of surfactants having an overall HLB number of between 5 and 15.

Claim 33 (new): The method of claim 19, wherein said surfactant or said mixture of surfactant comprises:

- ethoxylated derivatives of mannitan oleate having a number of OE of between 5 and 15;

- ethoxylated derivates of corn oil having a number of OE between 20 and 40 corn oil; or

- ethoxylated derivatives of castor oil having anumber of OE equal to 7 or equal to 60.